<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831699</url>
  </required_header>
  <id_info>
    <org_study_id>Zik01</org_study_id>
    <nct_id>NCT02831699</nct_id>
  </id_info>
  <brief_title>The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico</brief_title>
  <acronym>Zik01</acronym>
  <official_title>The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mexican Emerging Infectious Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Secretaria de Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mexican Emerging Infectious Diseases Clinical Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate subjects with fever and/or rash to determine the percentage of those&#xD;
      infected by the Zika, Chikungunya, or Dengue virus. The study will also compare the clinical&#xD;
      signs, symptoms, and lab abnormalities related to each virus, to better specify each virus's&#xD;
      characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll subjects in several different cohorts including a febrile rash cohort&#xD;
      (attempting to capture acute Zika/Chikungunya/Dengue infection), a household cohort&#xD;
      (attempting to capture asymptomatic or minimally symptomatic subjects), and a cohort of those&#xD;
      with Guillain Barré). Additionally, two subpopulations of the febrile rash cohort that have&#xD;
      special follow up. This includes the pregnant population, who will be followed through&#xD;
      delivery to determine pregnancy outcomes, and those subjects with neurologic or cognitive&#xD;
      manifestations who will be evaluated to determine the spectrum of neurologic disease seen&#xD;
      with these diseases.&#xD;
&#xD;
      Subjects with Guillain Barré with potential exposure to Zika virus are of special interest&#xD;
      given the severity of disease. Subjects with Guillian Barré do not need to have a preceding&#xD;
      illness suggestive of Zika or other viruses. As there are few subjects with Guillain Barré,&#xD;
      subjects will be enrolled in two ways - a prospective cohort for subjects with acute Guillain&#xD;
      Barré, and a cohort for subjects that had Guillain Barré in the last several years. Data&#xD;
      collected systematically from these cohorts will improve the understanding of&#xD;
      Zika/Chikungunya/Dengue virus infections.&#xD;
&#xD;
      There are many uncertainties about the number of subjects that meet this case definition.&#xD;
      There are limits to the ability to enroll based on staffing and other resources. If there are&#xD;
      many cases, an emphasis will be placed on enrolling pregnant subjects and adults with&#xD;
      neurologic complications that meet the case definition, as this is the area of highest&#xD;
      clinical need. If there are few pregnant women or subjects with neurologic problems that can&#xD;
      be enrolled, then any adults or children meeting the criteria can be enrolled. Not all&#xD;
      cohorts will be active at all sites, based on the type of facility and type of patients&#xD;
      typically seen. If sufficient numbers of certain populations are enrolled (i.e. children born&#xD;
      to women infected with Zika), the protocol may be amended to study those populations in more&#xD;
      detail.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2016</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects that have confirmed Zika, Chikungunya, or Dengue (including co-infections) from the subjects presenting with fever and/or rash in southeastern Mexico.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Zika Virus Disease (Disorder)</condition>
  <condition>Dengue</condition>
  <condition>Chikungunya</condition>
  <arm_group>
    <arm_group_label>Febrile Rash</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Household</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Guillain-Barré prospective</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Guillain-Barré</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine samples Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit male and female individuals of one year of age or older from&#xD;
        southeastern Mexico and neighboring areas who exhibit signs of rash and/or fever that may&#xD;
        be indicative Zika, Dengue, or Chikungunya. In addition, family members of these&#xD;
        individuals will asked to be participate whether they have symptoms or not. Pregnant women&#xD;
        will be included. Also, all individuals with a prior diagnosis of Guillain-Barré or history&#xD;
        suggestive of Guillain-Barré will be asked to enroll.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Febrile Rash Cohort Inclusion Criteria:&#xD;
&#xD;
        Subjects with fever and/or rash will be included if they are 1 year of age or older, and&#xD;
        meet one of the following criteria (1 or 2):&#xD;
&#xD;
          1. Meeting the WHO/PAHO case definition, as defined as (a and b and c):&#xD;
&#xD;
               1. One or both of the following primary signs:&#xD;
&#xD;
                    -  Rash&#xD;
&#xD;
                    -  Elevated body temperature (&gt; 37.2 °C) AND&#xD;
&#xD;
               2. One or more of the following symptoms (not explained by other medical&#xD;
                  conditions):&#xD;
&#xD;
                    -  Arthralgia&#xD;
&#xD;
                    -  Myalgia&#xD;
&#xD;
                    -  Non-purulent conjunctivitis or conjunctival hyperemia&#xD;
&#xD;
                    -  Headache&#xD;
&#xD;
                    -  Malaise AND&#xD;
&#xD;
               3. Onset of illness in the last 7 days&#xD;
&#xD;
          2. Modified case definition (a and b):&#xD;
&#xD;
               1. Any two of the following:&#xD;
&#xD;
                    -  Rash&#xD;
&#xD;
                    -  Elevated body temperature (&gt; 37.2 °C)&#xD;
&#xD;
                    -  Arthralgia&#xD;
&#xD;
                    -  Myalgia&#xD;
&#xD;
                    -  Non-purulent conjunctivitis or conjunctival hyperemia&#xD;
&#xD;
                    -  Headache&#xD;
&#xD;
                    -  Malaise AND&#xD;
&#xD;
               2. Onset of illness in the last 7 days&#xD;
&#xD;
        Household Cohort Inclusion Criteria:&#xD;
&#xD;
          1. 1 year of age and older, and&#xD;
&#xD;
          2. Either live in the same household as a subject enrolled into the febrile rash cohort&#xD;
             OR live in the same household as a subject who is experiencing an illness similar to&#xD;
             Zika (fever and rash as previously described), regardless if said subject is enrolled&#xD;
             in the study.&#xD;
&#xD;
        Guillain-Barré Prospective Cohort Inclusion Criteria:&#xD;
&#xD;
        Either confirmed or suspected Guillain-Barré (areflexic flaccid paralysis) as defined&#xD;
        either of the following:&#xD;
&#xD;
          1. Confirmed Guillain-Barré&#xD;
&#xD;
               1. Acute onset of weakness or paralysis (from baseline to full weakness in 20 days)&#xD;
&#xD;
               2. Weakness is symmetrical&#xD;
&#xD;
               3. Areflexic (reflexes are 0/4)&#xD;
&#xD;
          2. Suspected Guillain-Barré&#xD;
&#xD;
               1. Acute onset of illness&#xD;
&#xD;
               2. Areflexic flaccid paralysis&#xD;
&#xD;
        Prior Guillain-Barré Cohort Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed Guillain-Barré&#xD;
&#xD;
               1. Acute onset of weakness or paralysis (from baseline to full weakness in 7 days)&#xD;
&#xD;
               2. Weakness is symmetrical&#xD;
&#xD;
               3. Areflexic (reflexes are 0/4)&#xD;
&#xD;
               4. Diagnosis since January 2014&#xD;
&#xD;
          2. Suspected Guillain-Barré&#xD;
&#xD;
               1. Acute onset of illness&#xD;
&#xD;
               2. Areflexic flaccid paralysis&#xD;
&#xD;
               3. Clinical diagnosis of Guillain-Barré&#xD;
&#xD;
               4. Diagnosis since January 2014&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophia Siddiqui</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Ruiz-Palacios</last_name>
    <role>Study Chair</role>
    <affiliation>Mexican Emerging Infectious Diseases Clinical Research Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Francisco Belaunzarán Zamudio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Tapachula</name>
      <address>
        <city>Tapachula</city>
        <state>Chiapas</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad Ciudad Salud</name>
      <address>
        <city>Chiapas</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Clínica Hospital Dr. Roberto Nettel Flores</name>
      <address>
        <city>Chiapas</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Hospital General de Zona con Medicina Familiar No. 1</name>
      <address>
        <city>Chiapas</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Unidad de Medicina Familiar No. 11</name>
      <address>
        <city>Chiapas</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Ciudad de México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zika</keyword>
  <keyword>Guillain Barré</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
    <mesh_term>Chikungunya Fever</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

